Argires Marotti now offers a groundbreaking therapy for the treatment of chronic pain. The Senza® SCS system, which delivers Nevro's proprietary HF10®, is an FDA-approved spinal cord stimulator (SCS) that has demonstrated superior results compared to traditional SCS for the treatment of back and leg pain in a large multicenter study in the United States.
HF10 is clinically proven to offer substantial pain relief without the tingling or buzzing used to mask pain in traditional spinal cord stimulation. Patients suffering debilitating pain need alternatives to opioids. In a clinical study, HF10 patients demonstrated an average reduction in use of opioid medications of nearly 70%.”
Over 100 million Americans suffer from common chronic pain. It is the primary cause of adult disability in the U.S. and is a costly public health issue. The combined loss of productivity and healthcare costs exceeds $600 billion annually in the U.S. [citation?] Severe pain can significantly interfere with a person's quality of life and functionality, yet the condition is largely under-treated and misunderstood.
Spinal cord stimulation represents another option to treat chronic pain. It involves the delivery of electrical signals to the spinal cord in order to alter pain signals to the brain. The electrical pulses are delivered by small electrodes on leads that are placed near the spinal cord and are connected to a compact, battery-powered generator implanted under the skin. SCS is a reversible therapy that has helped hundreds of thousands of people experience relief from chronic pain.
HF10 represents a significant advance in spinal cord stimulation. FDA approval for HF10 included superiority labeling over traditional SCS therapy, validating that HF10 reduces pain more effectively in more patients. Additionally, HF10 is the only SCS therapy indicated to deliver pain relief without paresthesia (a stimulation-induced sensation, such as tingling, burning, or pricking, which is the basis of traditional SCS) and is the only SCS system approved by the FDA to be used without patient restrictions on driving while receiving therapy.